Dr. Jeremy Levin is chairman and chief executive officer of Ovid Therapeutics Inc., a public company developing novel medicines to treat epilepsies and seizure-related disorders.
Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd.. Before Teva, Dr. Levin was a member of the executive committee Bristol-Myers Squibb Company. In that capacity, he was the architect, lead and implementer of the String of Pearls Strategy, which transformed Bristol and facilitated the dawn and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin joined Bristol from Novartis, where he was the global head of strategic alliances.
Dr. Levin was voted as one of the 25 most influential biotechnology leaders by FierceBiotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020 and 2021. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. In June 2020, he edited and published the best seller “Biotechnology in the Time of Covid-19”.
He has served as a member of the board of directors of various public and private biopharmaceutical companies. Dr. Levin is the chairman of Opthea, the past Chairman and current board member of the Biotechnology Innovation Organization (BIO) and is currently a member of the board of directors of Lundbeck.
Dr. Levin has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned a First-Class BA in Zoology, winning the University Prize, and subsequently, was awarded a MA and Doctorate in chromatin structure, at the University of Oxford. Thereafter, he earned his medical and surgical degrees from the University of Cambridge, where he won the Kermode Prize for his work on Captopril.